Tradestie Institutional Equity Comparison Engine
LYRA vs BDTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BDTX Overall Edge
BDTX Captures Institutional Edge (4โ0 Pillars ยท 8โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Black Diamond Therapeutics, Inc. Common Stock (BDTX) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, LYRA trades at N/M Forward P/E with -25032.0% operating margin (-87.2% YoY revenue) versus BDTX at 8.3x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BDTX sits in BREAKDOWN (55th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
BDTX
LYRA N/M vs BDTX 8.3x Fwd P/E
Growth & Margin Winner
BDTX
Op Margin -25032.0% vs 0.0% ยท YoY -87.2% vs +0.0%
Momentum & Technical Winner
BDTX
1Y -94.3% vs -64.8% ยท 52W Pos 1% vs 1%
Options & Structure Winner
BDTX
UNCLASSIFIED (N/A IV) vs BREAKDOWN (55th %ile IV)
LYRA
NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap
$2.3M
1M Return
-62.5%
1Y Return
-94.34%
Forward P/E
N/M
Unified AI Score
52.2 / 100
HOLD
Tech 60.0
Fund 56.0
Flow 50.0
Mom 59.0
BDTX
NASDAQ
Black Diamond Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.41
-7.84% 1D
Market Cap
$84.5M
1M Return
-22.1%
1Y Return
-64.84%
Forward P/E
8.3x
Unified AI Score
56.1 / 100
HOLD
Tech 60.0
Fund 56.0
Flow 70.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
LYRA -94.34%
BDTX -64.84%
Spread: +41.75 pp (BDTX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LYRA Revenue | BDTX Revenue | LYRA Op. Margin | BDTX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2021 | $0M | N/A | -15303.5% | N/A | LYRA |
| FY2022 | $0M | N/A | -4131.0% | N/A | LYRA |
| FY2023 | $0M | N/A | -4308.1% | N/A | LYRA |
| FY2024 | $0M | N/A | -6280.8% | N/A | LYRA |
| FY2025 | $0M | $70M | -7794.5% | 17.9% | BDTX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LYRA | BDTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.3M | $84.5M | Larger Scale | BDTX |
| Trailing P/E Ratio Valuation | N/M | 8.3x | Lower Multiple | BDTX |
| Forward P/E Ratio Valuation | N/M | 8.3x | Lower Multiple | BDTX |
| Revenue Growth (YoY) Growth | -87.2% | +0.0% | Higher Growth | BDTX |
| Operating Margin (TTM) Profitability | -25032.0% | 0.0% | Higher Margin | BDTX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -404.5% | -41.1% | Higher ROE | BDTX |
| 52-Week Range Position Momentum | 1% ($0โ$38) | 1% ($1โ$4) | Stronger Trend | LYRA |
| Beta / 30D Volatility Risk Regime | 0.33ฮฒ ยท 248% Vol | 1.80ฮฒ ยท 111% Vol | Lower Realized Risk | BDTX |
| Unified Institutional Score Composite Signal | 52.2 / 100 (HOLD) | 56.1 / 100 (HOLD) | Higher Composite | BDTX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full LYRA vs BDTX Buy Guide
LYRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
BDTX
BREAKDOWN
125d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
55th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither LYRA nor BDTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.